Corporate PresentationDownload January 2025 Presentation Select HighlightsFebruary 11, 2025Oppenheimer Healthcare Life Sciences ConferenceAccess Webcast »January 15, 2025J.P. Morgan Healthcare ConferenceView Presentation »May 17, 2024STAT3 Plenary Presentation at Society for Investigative Dermatology (SID) Annual MeetingView Presentation » Latest Press ReleasesFebruary 10, 2025Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceRead More »January 10, 2025Recludix Pharma to Present at the Annual J.P. Morgan Healthcare ConferenceRead More »November 25, 2024Recludix Pharma to Participate in Two Investor Conferences in DecemberRead More »November 14, 2024Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory ArthritisRead More » More Press Releases Events and PresentationsFebruary 11, 2025Oppenheimer Healthcare Life Sciences ConferenceAccess Webcast »January 15, 2025J.P. Morgan Healthcare ConferenceView Presentation »May 17, 2024STAT3 Plenary Presentation at Society for Investigative Dermatology (SID) Annual MeetingView Presentation »December 7, 2023STAT6 Program Highlighted in Sanofi R&D DayAccess Webcast » More Events and Presentations News Coverage HighlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead More »July 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead More »July 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read More »July 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead More »July 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead More »
